ARA-290 (Cibinetide)
Also known as: ARA-290, Cibinetide
ARA-290 (Cibinetide) is an 11-amino-acid peptide derived from erythropoietin, studied for nerve repair and reducing neuropathic pain without affecting red blood cells.
Last updated
Mechanism of Action
ARA-290 is a short peptide modeled on the helix-B region of erythropoietin (EPO) that selectively activates the innate repair receptor, a heteromer of the EPO receptor and the beta-common (CD131) receptor. Unlike full-length EPO, it does not bind the homodimeric EPO receptor, so it produces tissue-protective and anti-inflammatory signaling without stimulating erythropoiesis. Activation of this pathway dampens pro-inflammatory cytokine release, promotes survival of neurons and small nerve fibers, and supports tissue repair, which is why it is investigated in neuropathic pain and sarcoidosis.
- Half-life
- Short; approximately 2 minutes in plasma, with effects outlasting clearance
- Administration Routes
- subcutaneous
- Research Status
- Research Chemical
Reported Benefits
- Studied for reducing neuropathic pain in small-fiber neuropathy
- Anti-inflammatory without raising red blood cell count
- May support small nerve fiber regeneration
- Investigated in sarcoidosis and diabetic neuropathy
- Tissue-protective EPO signaling without erythropoietic risk
Potential Side Effects
- Generally well tolerated in trials
- Possible mild injection-site reactions
- Limited long-term safety data
- Headache or fatigue reported in some subjects
Common Dosing
For research use only: clinical trials used roughly 2-4 mg subcutaneously once daily for limited courses. Not personal medical advice.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Known hypersensitivity to the peptide
- Pregnancy and breastfeeding (insufficient data)
- Use without clinical oversight in active malignancy
KPV
KPV is a tripeptide derived from the C-terminus of alpha-MSH that exerts anti-inflammatory effects without pigmentary activity. It is studied for gut inflammation, wound healing, and skin conditions.
BPC-157
A synthetic peptide fragment derived from a protein found in gastric juice, studied for its broad tissue-healing and cytoprotective effects. Popular in research for tendon, ligament, muscle, and gut repair.
SS-31 (Elamipretide)
SS-31 (elamipretide) is a mitochondria-targeted tetrapeptide studied for protecting mitochondrial function in conditions involving oxidative stress and energy failure. It has been investigated clinically for mitochondrial myopathy and heart and kidney disease.
- View
ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density
2013
- View
Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study
2012
- View
ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes
2015
- View
Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain
2017